Competitor Analysis RNA Therapeutics in Clinical Development
Product description
The present Competitive Intelligence Report about RNA Therapeutics in Clinical Development provides a competitor evaluation in the field of RNA based molecules being developed in clinical studies for treatment of a variety of clinical disorders as of February 2011. RNA based Therapetuics include antisense molecules, aptamers, Locked Nucleic Acid (LNA) RNA, siRNA/RNAi and CpG oligonucleotides. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Although there are only two approved and marketed RNA based Therapeutics and despite the recent terminations of Big Pharma collaboration with RNA companies, there are more than 65 RNA based different molecules under clinical investigation. The report includes a compilation of currently active projects in clinical research and development of antisense, aptamer, LNA RNA, RNAi and CpG oligonucleotide therapeutics for treatment of a variety of clinical disorders. In addition, the report lists company-specific R&D pipelines of RNA Therapeutics in Clinical Develompent. Competitor projects are listed in a tabular format providing information on:
Index
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
The present Competitive Intelligence Report about RNA Therapeutics in Clinical Development provides a competitor evaluation in the field of RNA based molecules being developed in clinical studies for treatment of a variety of clinical disorders as of February 2011. RNA based Therapetuics include antisense molecules, aptamers, Locked Nucleic Acid (LNA) RNA, siRNA/RNAi and CpG oligonucleotides. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Although there are only two approved and marketed RNA based Therapeutics and despite the recent terminations of Big Pharma collaboration with RNA companies, there are more than 65 RNA based different molecules under clinical investigation. The report includes a compilation of currently active projects in clinical research and development of antisense, aptamer, LNA RNA, RNAi and CpG oligonucleotide therapeutics for treatment of a variety of clinical disorders. In addition, the report lists company-specific R&D pipelines of RNA Therapeutics in Clinical Develompent. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and additional comments with a hyperlink leading to the source of information.
Index
- Antisense RNA
- LNA RNA (translational arrest)
- Aptamers
- RNAi/siRNA
- Immunostimulatory CpG Oligonucleotides
- Corporate Clinical Stage RNA Therapeutics R&D Pipelines
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
